Yamane Kenichi, Ihn Hironobu, Asano Yoshihide, Jinnin Masatoshi, Tamaki Kunihiko
Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
J Immunol. 2003 Oct 1;171(7):3855-62. doi: 10.4049/jimmunol.171.7.3855.
Transforming growth factor-beta stimulates the production of the extracellular matrix, whereas TNF-alpha has antifibrotic activity. Understanding the molecular mechanism underlying the antagonistic activities of TNF-alpha against TGF-beta is critical in the context of tissue repair and maintenance of tissue homeostasis. In the present study, we demonstrated a novel mechanism by which TNF-alpha blocks TGF-beta-induced gene and signaling pathways in human dermal fibroblasts. We showed that TNF-alpha prevents TGF-beta-induced gene trans activation, such as alpha2(I) collagen or tissue inhibitor of metalloproteinases 1, and TGF-beta signaling pathways, such as Smad3, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinases, without inducing levels of inhibitory Smad7 in human dermal fibroblasts. TNF-alpha down-regulates the expression of type II TGF-beta receptor (TbetaRII) proteins, but not type I TGF-beta receptor (TbetaRI), in human dermal fibroblasts. However, neither TbetaRII mRNA nor TbetaRII promoter activity was decreased by TNF-alpha. TNF-alpha-mediated decrease of TbetaRII protein expression was not inhibited by the treatment of fibroblasts with either a selective inhibitor of I-kappaB-alpha phosphorylation, BAY 11-7082, or a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, PD98059. Calpain inhibitor I (ALLN), a protease inhibitor, inhibits TNF-alpha-mediated down-regulation of TbetaRII. We found that TNF-alpha triggered down-regulation of TbetaRII, leading to desensitization of human dermal fibroblasts toward TGF-beta. Furthermore, these events seemed to cause a dramatic down-regulation of alpha2(I) collagen and tissue inhibitor of metalloproteinases 1 in systemic sclerosis fibroblasts. These results indicated that TNF-alpha impaired the response of the cells to TGF-beta by regulating the turnover of TbetaRII.
转化生长因子-β刺激细胞外基质的产生,而肿瘤坏死因子-α具有抗纤维化活性。在组织修复和维持组织稳态的背景下,了解肿瘤坏死因子-α对抗转化生长因子-β的拮抗活性的分子机制至关重要。在本研究中,我们证明了一种新的机制,通过该机制肿瘤坏死因子-α可阻断转化生长因子-β诱导的人皮肤成纤维细胞中的基因和信号通路。我们发现肿瘤坏死因子-α可阻止转化生长因子-β诱导的基因转录激活,如α2(I)型胶原或金属蛋白酶组织抑制剂1,以及转化生长因子-β信号通路,如Smad3、c-Jun氨基末端激酶和p38丝裂原活化蛋白激酶,而不会在人皮肤成纤维细胞中诱导抑制性Smad7的水平。肿瘤坏死因子-α下调人皮肤成纤维细胞中II型转化生长因子-β受体(TβRII)蛋白的表达,但不会下调I型转化生长因子-β受体(TβRI)的表达。然而,肿瘤坏死因子-α既不会降低TβRII mRNA水平,也不会降低TβRII启动子活性。用I-κB-α磷酸化的选择性抑制剂BAY 11-7082或丝裂原活化蛋白激酶/细胞外信号调节激酶抑制剂PD98059处理成纤维细胞,均不会抑制肿瘤坏死因子-α介导的TβRII蛋白表达降低。蛋白酶抑制剂钙蛋白酶抑制剂I(ALLN)可抑制肿瘤坏死因子-α介导的TβRII下调。我们发现肿瘤坏死因子-α引发TβRII的下调,导致人皮肤成纤维细胞对转化生长因子-β脱敏。此外,这些事件似乎导致系统性硬化症成纤维细胞中α2(I)型胶原和金属蛋白酶组织抑制剂1的显著下调。这些结果表明,肿瘤坏死因子-α通过调节TβRII的周转损害细胞对转化生长因子-β的反应。